Literature DB >> 27736260

R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients.

Pernille Svendsen1, Nitesh Shekhrajka2, Kasper Lindblad Nielsen1,3, Peter Vestergaard3,4, Mette Østergaard Poulsen1, Anders Krog Vistisen1,5, Peter Svenssen Munksgaard1, Marianne Tang Severinsen1, Paw Jensen1, Hans Erik Johnsen1,3, Lasse Hjort Jakobsen1,3, Martin Bøgsted1,3, Jens Brøndum Frøkjær2,3, Tarec Christoffer El-Galaly1,3.   

Abstract

Treatment of diffuse large B-cell lymphoma (DLBCL) with R-CHOP(-like) regimens include large cumulative doses of prednisolone. In this retrospective study, we evaluated changes in vertebral bone density (VD) in DLBCL patients by measuring CT-ascertained Hounsfield units (HU) at the L3 level. In total, 111 patients diagnosed from 2007 to 2012 and response assessed following first line treatment were included. Post-treatment VD was significantly reduced to 86% of pretreatment VD on average (p < .001). Neither female sex nor high age (>70 years) were significantly associated with greater post-treatment VD reduction. Two years after completing R-CHOP treatment, VD remained significantly lower than baseline VD (p < .001). Vertebral compression fractures visualized by CT were found in 16/111 patients (14%) during follow-up. In conclusion, bone mineral density is significantly reduced following R-CHOP(-like) treatment and vertebral compression fractures are common. Glucocorticoid-induced osteoporosis may therefore have impact on survivorship for the large fraction of DLBCL patients with durable remissions.

Entities:  

Keywords:  Diffuse large B-cell lymphoma; Hounsfield units; R-CHOP; bone mineral density; computed tomography

Mesh:

Substances:

Year:  2016        PMID: 27736260     DOI: 10.1080/10428194.2016.1233543

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.

Authors:  Stephen Booth; Hannah Plaschkes; Amy A Kirkwood; Adam Gibb; Patrick Horgan; Claire Higham; Joanna M Oladipo; Joe Browning; Usman Khan; Bing Tseu; Lucia Chen; John Willan; Julia Wolf; Arief Gunawan; Paul Fields; Tim Ebsworth; Robert Lown; Dominic Gordon-Walker; Nimish Shah; Kim M Linton; Graham P Collins; Jaimal Kothari; Catherine Hildyard; Toby A Eyre
Journal:  Blood Adv       Date:  2020-09-22

2.  Impact of Diffuse Large B-Cell Lymphoma on Mammography and Bone Density Testing in Women.

Authors:  Rahul Garg; Usha Sambamoorthi; Xi Tan; Soumit K Basu; Treah Haggerty; Kimberly M Kelly
Journal:  J Prim Prev       Date:  2021-03-12

3.  Reduction of the Vertebral Bone Mineral Density in Patients with Hodgkin Lymphoma Correlates with Their Age and the Treatment Regimen They Received.

Authors:  Nadav Ofshenko; Eyal Bercovich; Tania Mashiach; Michal Weiler-Sagie; Daniela Militianu; Eldad J Dann
Journal:  Cancers (Basel)       Date:  2022-01-19       Impact factor: 6.639

4.  High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas.

Authors:  Li-Wen Huang; Dong Sun; Thomas M Link; Thomas Lang; Weiyun Ai; Lawrence D Kaplan; Michael A Steinman; Charalambos Andreadis
Journal:  Support Care Cancer       Date:  2021-03-10       Impact factor: 3.603

5.  Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study.

Authors:  Konstantinos Anargyrou; Despina Fotiou; Theodoros P Vassilakopoulos; Dimitrios Christoulas; Polyzois Makras; Maria Dimou; Ioannis Ntanasis-Stathopoulos; Stavroula Masouridou; Maria K Angelopoulou; Athanasios Papatheodorou; Konstantinos Tsionos; Panayiotis Panayiotidis; Meletios A Dimopoulos; Evangelos Terpos
Journal:  Hemasphere       Date:  2019-09-24

6.  Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice.

Authors:  Albert Kolomansky; Irit Kaye; Nathalie Ben-Califa; Anton Gorodov; Zamzam Awida; Ofer Sadovnic; Maria Ibrahim; Tamar Liron; Sahar Hiram-Bab; Howard S Oster; Nadav Sarid; Chava Perry; Yankel Gabet; Moshe Mittelman; Drorit Neumann
Journal:  Front Immunol       Date:  2020-10-19       Impact factor: 7.561

Review 7.  Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi.

Authors:  Sergio Di Molfetta; Antonella Daniele; Chiara Gerardi; Eleonora Allocati; Carla Minoia; Giacomo Loseto; Francesco Giorgino; Attilio Guarini; Vitaliana De Sanctis
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

8.  A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment.

Authors:  Paw Jensen; Lasse Hjort Jakobsen; Martin Bøgsted; Joachim Baech; Simon Lykkeboe; Marianne Tang Severinsen; Peter Vestergaard; Tarec Christoffer El-Galaly
Journal:  Blood Adv       Date:  2022-04-26

9.  Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma.

Authors:  Tanaya Shree; Qian Li; Sally L Glaser; Ann Brunson; Holden T Maecker; Robert W Haile; Ronald Levy; Theresa H M Keegan
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 50.717

10.  Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures.

Authors:  J Bodden; D Sun; G B Joseph; L-W Huang; C Andreadis; M Hughes-Fulford; T F Lang; T M Link
Journal:  Osteoporos Int       Date:  2020-08-15       Impact factor: 5.071

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.